|View printer-friendly version|
|April 23, 2006 1:38 p.m.|
|Teva Provides Update on Generic Pravachol®|
Jerusalem, Israel, April 23, 2006 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that further to its press release dated April 20, 2006, the U.S. Court of Appeals for the DC Circuit has issued a stay of approval of all Abbreviated New Drug Applications (ANDAs) to market a generic version of Bristol-Myers Squibb's Pravachol® (Pravastatin Sodium) Tablets. In so ordering, the Court stated that the purpose of this administrative injunction is to give the court sufficient opportunity to consider the merits of Apotex's motion for injunctive relief pending appeal and should not be construed in any way as a ruling on the merits of that motion.